Neurizon Therapeutics Gets Ethics Committee Nod for Neurodegenerative Disease Phase 1 Study; Shares Gain 3%

MT Newswires Live05-13

Neurizon Therapeutics (ASX:NUZ) said the Bellberry Human Research Ethics Committee approved its phase 1 study to develop the NUZ-001 oral liquid formulation as a potential treatment for amyotrophic lateral sclerosis (ALS), according to a Wednesday filing with the Australian bourse.

ALS is a neurodegenerative disorder associated with progressive impairment in speech and swallowing function.

The phase 1 trial will enroll 32 healthy volunteers in Australia with the aim of generating safety and other data to guide formulation development and the broader program for NUZ-001, the company said.

The study is scheduled to start in the third quarter and be completed in the fourth quarter.

Neurizon Therapeutics shares gained 3% in recent Wednesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635222831?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 08:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635222831","market":"us","top_or_hot":-1,"title":"Neurizon Therapeutics Gets Ethics Committee Nod for Neurodegenerative Disease Phase 1 Study; Shares Gain 3%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PAAFF\">Neurizon Therapeutics</a> (ASX:NUZ) said the Bellberry Human Research Ethics Committee approved its phase 1 study to develop the NUZ-001 oral liquid formulation as a potential treatment for amyotrophic lateral sclerosis (ALS), according to a Wednesday filing with the Australian bourse.</p><p>ALS is a neurodegenerative disorder associated with progressive impairment in speech and swallowing function.</p><p>The phase 1 trial will enroll 32 healthy volunteers in Australia with the aim of generating safety and other data to guide formulation development and the broader program for NUZ-001, the company said.</p><p>The study is scheduled to start in the third quarter and be completed in the fourth quarter.</p><p><a href=\"https://laohu8.com/S/NUZ.AU\">Neurizon Therapeutics</a> shares gained 3% in recent Wednesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurizon Therapeutics Gets Ethics Committee Nod for Neurodegenerative Disease Phase 1 Study; Shares Gain 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurizon Therapeutics Gets Ethics Committee Nod for Neurodegenerative Disease Phase 1 Study; Shares Gain 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-13 08:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PAAFF\">Neurizon Therapeutics</a> (ASX:NUZ) said the Bellberry Human Research Ethics Committee approved its phase 1 study to develop the NUZ-001 oral liquid formulation as a potential treatment for amyotrophic lateral sclerosis (ALS), according to a Wednesday filing with the Australian bourse.</p><p>ALS is a neurodegenerative disorder associated with progressive impairment in speech and swallowing function.</p><p>The phase 1 trial will enroll 32 healthy volunteers in Australia with the aim of generating safety and other data to guide formulation development and the broader program for NUZ-001, the company said.</p><p>The study is scheduled to start in the third quarter and be completed in the fourth quarter.</p><p><a href=\"https://laohu8.com/S/NUZ.AU\">Neurizon Therapeutics</a> shares gained 3% in recent Wednesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2635222831","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635222831","pubTimestamp":1778633814,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neurizon Therapeutics  said the Bellberry Human Research Ethics Committee approved its phase 1 study to develop the NUZ-001 oral liquid formulation as a potential treatment for amyotrophic lateral sclerosis , according to a Wednesday filing with the Australian bourse.ALS is a neurodegenerative disorder associated with progressive impairment in speech and swallowing function.The phase 1 trial will enroll 32 healthy volunteers in Australia with the aim of generating safety and other data to guide formulation development and the broader program for NUZ-001, the company said.The study is scheduled to start in the third quarter and be completed in the fourth quarter.Neurizon Therapeutics shares gained 3% in recent Wednesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","BK4539":"次新股","BK4139":"生物科技","LENZ":"Therapeutics","NUZ.AU":"NEURIZON THERAPEUTICS LTD","BK4007":"制药"},"translate_title":"Neurizon Therapeutics神经退行性疾病1期研究获得伦理委员会批准；股价上涨3%","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"NUZ.AU":1},"content_text":"Neurizon Therapeutics (ASX:NUZ) said the Bellberry Human Research Ethics Committee approved its phase 1 study to develop the NUZ-001 oral liquid formulation as a potential treatment for amyotrophic lateral sclerosis (ALS), according to a Wednesday filing with the Australian bourse.ALS is a neurodegenerative disorder associated with progressive impairment in speech and swallowing function.The phase 1 trial will enroll 32 healthy volunteers in Australia with the aim of generating safety and other data to guide formulation development and the broader program for NUZ-001, the company said.The study is scheduled to start in the third quarter and be completed in the fourth quarter.Neurizon Therapeutics shares gained 3% in recent Wednesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635222831","isCrawlerRequest":true}